The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Here comes a prescription version of generic Zyrtec syrup. At first glance, we wonder how it will compete with over the counter Zyrtec. But wait...there may be a market for this drug
Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report. Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...
mY 6 PERSON GROUP HAS INSTALLED AN EXPENSIVE EMR ABOUT 6 MONTHS AGO . WHILE IT HAS BENEFITED US IN MANY WAYS (BETTER RECORD KEEPING FOR EXAMPLE) IT HAS BEEN VERY EXPENSVE TO INSTALL AND IMPLEMENT (HAVING TO HIRE A TECH GUY TO HELP US WT SERVER CRASHES , ETC THAT OCCUR WEEKLY). IN ADDITION THE...
A direct comparison between liraglutide and exenatide is the best way to show liraglutide's true benefit as a GLP-1 analogue. Novo Nordisk did just that and the results bode well for liraglutide. Once daily liraglutide will soon replace exenatide, given its equivalent efficacy in reducing HbA1c and...
This drug seems much more effective at reducing free-IgE levels than is Xolair. Overall, Xolair has given many patients a tremendous improvement in their quality of life, but it hasn't fulfilled many of its promises. Frankly, some of Xolair's benefits are disappointing, particularly in the 40...
more prescribing habits of a more potent antibody. It also would be preferred for those patients whose IgE levels are too great fro treatment with Xolair.
Calling a 0.89% improvement "significant" just seems to me to show the weakness of this current trial. Anyone can use statistics to prove just about anything. Using verbal manipulation to puff up a study's result is unfair, unreliable and just plain sad.
When the new administration come in, medicine and big pharma are both going to be hit hard. Industry sponsored research is going to be examined with a fine tooth comb. All we need is another scandal. It's getting harder and harder to trust industry sponsored research, with news coming...
This Circulation paper is the first peer reviewed data on the 2 pivotal Phase III trials on ambrisentan that lead the FDA to approving it for the treatment of PAH in July 2007. This paper is critically important since all new research needs to withstand the rigor of peer-review for...